A CD21 low phenotype, with no evidence of autoantibodies to complement proteins, is consistent with a poor prognosis in CLL

Por Nichols, Eva-Maria, Jones, Rachel, Watson, Rachael, Pepper, Chris J., Fegan, Chris, Marchbank, Kevin J.
Publicado no Oncotarget (2015)